Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medlive Technology Co's cash flow for dividends for the
six
months ended in Dec. 2025 was HK$-94.4 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-203.8 Mil.
Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.
Medlive Technology Co's quarterly payment of dividends
increased
from Dec. 2024 (HK$-94.3 Mil) to Jun. 2025 (HK$-109.4 Mil) but then
declined
from Jun. 2025 (HK$-109.4 Mil) to Dec. 2025 (HK$-94.4 Mil).
Medlive Technology Co's annual payment of dividends
increased
from Dec. 2023 (HK$-136.4 Mil) to Dec. 2024 (HK$-191.2 Mil) and
increased
from Dec. 2024 (HK$-191.2 Mil) to Dec. 2025 (HK$-205.0 Mil).
Medlive Technology Co Cash Flow for Dividends Related Terms
Medlive Technology Co Cash Flow for Dividends Historical Data
* Premium members only.
The historical data trend for Medlive Technology Co's Cash Flow for Dividends can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medlive Technology Co Cash Flow for Dividends Chart
Medlive Technology Co Cash Flow for Dividends Calculation
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Cash Flow for Dividends for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-203.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow for Dividends of HK$-203.8 Mil mean?
Medlive Technology Co (HKSE:02192) has a Cash Flow for Dividends of HK$-203.8 Mil as of Dec. 2025. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Medlive Technology Co and its competitors.
Is Medlive Technology Co's Cash Flow for Dividends too high?
Medlive Technology Co's current Cash Flow for Dividends is HK$-203.8 Mil. Overall, Medlive Technology Co has a GF Score™ of 90/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medlive Technology Co's Cash Flow for Dividends compare to VEEV and BTSG?
Medlive Technology Co's Cash Flow for Dividends of HK$-203.8 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Healthcare Providers & Services company?
A good Cash Flow for Dividends depends on the Healthcare Providers & Services industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Medlive Technology Co and its competitors. Medlive Technology Co's current Cash Flow for Dividends is HK$-203.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medlive Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Medlive Technology Co (HKSE:02192) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$14.95, compared to a current price of HK$7.87 — trading 47.4% below its estimated fair value. The current Cash Flow for Dividends is HK$-203.8 Mil. Medlive Technology Co's overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Medlive Technology Co (HKSE:02192), the current Cash Flow for Dividends is HK$-203.8 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medlive Technology Co (HKSE:02192) Overvalued in 2026?
Based on GuruFocus' analysis, Medlive Technology Co stock appears to be undervalued.
The current stock price of HK$7.87 is trading 47.4% below its estimated GF Value™ of HK$14.95.
GuruFocus considers Medlive Technology Co to be Significantly Undervalued.
Key valuation signals for HKSE:02192:
Cash Flow for Dividends: HK$-203.8 Mil
GF Value™: HK$14.95 vs. price of HK$7.87 (47.4% below fair value)
No single metric tells the full story. See the HKSE:02192 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medlive Technology Co Ltd is a digital healthcare marketing company that produces customized content for pharmaceutical and medical device firms. The company developed into a professional provider of medical information services and precision digital marketing services. Its platform also provides medical content consisting of third-party research, informal discussions, and medical news articles. The company also operates a minor internet hospital and a SaaS solution that helps with medical conferences and clinical research.
90GF Score
Get the complete analysis for HKSE:02192
Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02192 has been successfully added to your 
